Page last updated: 2024-10-23

astemizole and Myasthenia Gravis

astemizole has been researched along with Myasthenia Gravis in 1 studies

Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.
astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.

Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ruhatiya, OK1

Other Studies

1 other study available for astemizole and Myasthenia Gravis

ArticleYear
Exacerbation of myasthenia gravis by single dose of Respren (Ethnor) and Astemizole tablets.
    The Journal of the Association of Physicians of India, 1993, Volume: 41, Issue:5

    Topics: Aged; Astemizole; Dextromethorphan; Humans; Male; Myasthenia Gravis; Tablets

1993